BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17728205)

  • 1. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
    Weingart O; Rehan FA; Schulz H; Naumann F; Knauel I; Bohlius CB; Engert A
    J Natl Cancer Inst; 2007 Sep; 99(17):E1. PubMed ID: 17728205
    [No Abstract]   [Full Text] [Related]  

  • 2. Fourth biannual report of the Cochrane Haematological Malignancies Group.
    Kober T; Hülsewede H; Bohlius J; Engert A
    J Natl Cancer Inst; 2006 Apr; 98(8):E1. PubMed ID: 16622111
    [No Abstract]   [Full Text] [Related]  

  • 3. Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia.
    Herbst C; Monsef I; Skötz N; Engert A;
    J Natl Cancer Inst; 2008 Aug; 100(15):E1. PubMed ID: 18664654
    [No Abstract]   [Full Text] [Related]  

  • 4. Second biannual report of the Cochrane Haematological Malignancies Group.
    Kober T; Bohlius J; Trelle S; Engert A
    J Natl Cancer Inst; 2005 Apr; 97(7):E1. PubMed ID: 15812063
    [No Abstract]   [Full Text] [Related]  

  • 5. New concepts in treatment approaches and prognostic factors in aggressive NHL.
    Shipp M
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):107-9. PubMed ID: 16728917
    [No Abstract]   [Full Text] [Related]  

  • 6. Fifth biannual report of the Cochrane Haematologic Malignancies Group--Focus on multiple myeloma.
    Naumann F; Weingart O; Kruse E; Schulz H; Bohlius J; Hülsewede H; Engert A;
    J Natl Cancer Inst; 2006 Aug; 98(16):E2. PubMed ID: 16912255
    [No Abstract]   [Full Text] [Related]  

  • 7. Third biannual report of the Cochrane Haematological Malignancies Group.
    Kober T; Skoetz N; Trelle S; Bohlius J; Engert A;
    J Natl Cancer Inst; 2005 Aug; 97(16):E2. PubMed ID: 16106014
    [No Abstract]   [Full Text] [Related]  

  • 8. Biannual report of the Cochrane Haematological Malignancies Group.
    Trelle S; Higgins G; Kober T; Engert A
    J Natl Cancer Inst; 2004 Aug; 96(15):E2. PubMed ID: 15292394
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab maintenance stretches progression-free survival in patients with indolent NHL.
    Oncology (Williston Park); 2004 Sep; 18(10):1316. PubMed ID: 15526836
    [No Abstract]   [Full Text] [Related]  

  • 10. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
    Cheson BD
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):4-6. PubMed ID: 18998258
    [No Abstract]   [Full Text] [Related]  

  • 11. [Maintenance therapy with rituximab].
    Krankenpfl J; 2005; 43(7-10):222-4. PubMed ID: 16515293
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trials referral resource. Current clinical trials of the anti-CD20 monoclonal antibody rituximab.
    Davis T; Gore-Langton RE; Cheson BD
    Oncology (Williston Park); 2000 Oct; 14(10):1437, 1440-3. PubMed ID: 11098509
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical investigations in aggressive non-Hodgkin lymphoma.
    Jonathan F
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):7-8. PubMed ID: 18998259
    [No Abstract]   [Full Text] [Related]  

  • 14. Bar the windows but open the door to randomization.
    Ratain MJ
    J Clin Oncol; 2010 Jul; 28(19):3104-6. PubMed ID: 20516430
    [No Abstract]   [Full Text] [Related]  

  • 15. In focus: ECOG 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT).
    Clin Adv Hematol Oncol; 2004 Mar; 2(3):152. PubMed ID: 16166942
    [No Abstract]   [Full Text] [Related]  

  • 16. Diffuse large B-cell lymphoma.
    Habermann TM
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):suppl 4-5. PubMed ID: 16491628
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacologic characteristics and clinical activity of human rituximab anti-CD20 monoclonal antibody].
    Varaldo R; Gobbi M
    Ann Ital Med Int; 2003; 18(3):182-7. PubMed ID: 14621431
    [No Abstract]   [Full Text] [Related]  

  • 18. Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factors.
    Skoetz N; Weingart O; Monsef I; Bauer K; Brillant C; Herbst C; Kluge S; Engert A;
    J Natl Cancer Inst; 2009 May; 101(9):E1. PubMed ID: 19401542
    [No Abstract]   [Full Text] [Related]  

  • 19. [Malignant lymphoma].
    Mori T
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):162-6. PubMed ID: 17301521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [First antibody in oncology continues on a successful course].
    Papadopoulos DO
    Krankenpfl J; 2004; 42(5-6):162-5. PubMed ID: 15527227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.